Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections

Journal of Clinical Microbiology

Volumn 49, Issue 11, 2011, Pages 3912-3916

  Yasufuku, Tomihiko ^a   Shigemura, Katsumi ^a,b   Shirakawa, Toshiro ^a,c   Matsumoto, Minori ^a   Nakano, Yuzo ^a   Tanaka, Kazushi ^a   Arakawa, Soichi ^a   Kawabata, Masato ^c   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shinko Hospital   (Japan)

^c KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BACTERIAL DNA; COTRIMOXAZOLE; IMIPENEM; ISOLEUCINE; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DNA SEQUENCE; DRUG USE; ENTEROCOCCUS FAECALIS; FEMALE; GENDER; GENE MUTATION; GYRA GENE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARC GENE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; OFLOXACIN; RISK FACTORS; URINARY TRACT INFECTIONS; YOUNG ADULT;

ENTEROCOCCUS FAECALIS;

EID: 80355141552     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05549-11     Document Type: Article

References (29)

1. Al-Tawfiq, J. A., and A. A. Anani. 2009. Antimicrobial susceptibility pattern of bacterial pathogens causing urinary tract infections in a Saudi Arabian hospital. Chemotherapy 55:127-131.
2. Arslan, H., O. K. Azap, O. Ergonul, and F. Timurkaynak. 2005. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J. Antimicrob. Chemother. 56:914-918. (Pubitemid 41631917)
3. Aslangul, E., et al. 2006. Acquired gentamicin resistance by permeability impairment in Enterococcus faecalis. Antimicrob. Agents Chemother. 50: 3615-3621. (Pubitemid 44684872)
4. Brown, P., M. Ki, and B. Foxman. 2005. Acute pyelonephritis among adults: cost of illness and considerations for the economic evaluation of therapy. Pharmacoeconomics 23:1123-1142. (Pubitemid 41637754)
5. Caljouw, M. A., W. P. den Elzen, H. J. Cools, and J. Gussekloo. 2011. Predictive factors of urinary tract infections among the oldest old in the general population. A population-based prospective follow-up study. BMC Med. 9:57.
6. Chung, A., M. Arianayagam, and P. Rashid. 2010. Bacterial cystitis in women. Aust. Fam. Physician 39:295-298.
7. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A8 (Table M100-S19). Clinical and Laboratory Standards Institute, Wayne, PA.
8. Conceição, N., C. da C. de Oliveira, P. R. da Silva, B. G. Avila, and A. G. de Oliveira. 2011. Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study. Rev. Soc. Bras. Med. Trop. 44:177-181.
9. George, S., M. R. Hamblin, and A. Kishen. 2009. Uptake pathways of anionic and cationic photosensitizers into bacteria. Photochem. Photobiol. Sci. 8:788-795.
10. Ghanem, G., R. Hachem, Y. Jiang, R. F. Chemaly, and I. Raad. 2007. Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect. Control. Hosp. Epidemiol. 28:1054-1059. (Pubitemid 47345265)
11. Grohs, P., S. Houssaye, A. Aubert, L. Gutmann, and E. Varon. 2003. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones. Antimicrob. Agents Chemother. 47:3542-3547. (Pubitemid 37345717)
12. Hummel, A., W. H. Holzapfel, and C. M. Franz. 2007. Characterisation and transfer of antibiotic resistance genes from enterococci isolated from food. Syst. Appl. Microbiol. 30:1-7. (Pubitemid 44969476)
13. Ishikawa, K., et al. 2011. The nationwide study of bacterial pathogens associated with urinary tract infections conducted by the Japanese Society of Chemotherapy. J. Infect. Chemother. 17:126-138.
14. Kamicker, B. J., et al. 2008. Bacterial efflux pump inhibitors. Methods Mol. Med. 142:187-204.
15. Kanematsu, E., et al. 1998. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis. Antimicrob. Agents Chemother. 42:433-435. (Pubitemid 28114460)
16. Lee, E. W., M. N. Huda, T. Kuroda, T. Mizushima, and T. Tsuchiya. 2003. EfrAB, an ABC multidrug efflux pump in Enterococcus faecalis. Antimicrob. Agents Chemother. 47:3733-3738. (Pubitemid 37484980)
17. Mitsou, E. K., E. Kirtzalidou, P. Pramateftaki, and A. Kyriacou. 2010. Antibiotic resistance in faecal microbiota of Greek healthy infants. Benef. Microbes 1:297-306.
18. Muratani, T., and T. Matsumoto. 2004. Bacterial resistance to antimicrobials in urinary isolates. Int. J. Antimicrob. Agents 24:S28-31. (Pubitemid 39208856)
19. Onodera, Y., J. Okuda, M. Tanaka, and K. Sato. 2002. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV of Enterococcus faecalis. Antimicrob. Agents Chemother. 46:1800-1804. (Pubitemid 34535200)
20. Pagès, J. M., and L. Amaral. 2009. Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim. Biophys. Acta 1794:826-833.
21. Peña, C., et al. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:520-524.
22. Rattanaumpawan, P., P. Tolomeo, W. B. Bilker, N. O. Fishman, and E. Lautenbach. 2011. Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients. Epidemiol. Infect. 139: 955-961.
23. Rudy, M., M. Nowakowska, B. Wiechuła, M. Zientara, and H. Radosz- Komoniewska. 2004. Antibiotic susceptibility analysis of Enterococcus spp. isolated from urine. Przegl. Lek. 61:473-476. (In Polish.)
24. Sunagawa, S., et al. 2011. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong. J. Antibiot. 64:539-545.
25. Ulett, K. B., et al. 2009. Diversity of group B streptococcus serotypes causing urinary tract infection in adults. J. Clin. Microbiol. 47:2055-2060.
26. Vebø, H. C., M. Solheim, L. Snipen, I. F. Nes, and D. A. Brede. 2010. Comparative genomic analysis of pathogenic and probiotic Enterococcus faecalis isolates, and their transcriptional responses to growth in human urine. PLoS One 5:e12489.
27. Weigel, L. M., C. D. Steward, and F. C. Tenover. 1998. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob. Agents Chemother. 42:2661-2667. (Pubitemid 28462911)
28. Wickman, P. A., J. A. Black, E. Smith Moland, K. S. Thomson, and N. D. Hanson. 2006. In vitro development of resistance to DX-619 and other quinolones in enterococci. J. Antimicrob. Chemother. 58:1268-1273. (Pubitemid 44884151)
29. Yildirim, M., et al. 2007. Vancomycin and high-level aminoglycoside resistant Enterococcus carriage and the risk factors related to resistance in hospitalized patients. Mikrobiyol. Bul. 41:271-277.